Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study:

Keigo Chida,Daisuke Kotani,Yoshiaki Nakamura,Akihito Kawazoe,Yasutoshi Kuboki,Kohei Shitara,Takashi Kojima,Hiroya Taniguchi,Jun Watanabe,Itaru Endo,Takayuki Yoshino

Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study:

2021

Keigo Chida
Daisuke Kotani
Yoshiaki Nakamura
Akihito Kawazoe
Yasutoshi Kuboki
Kohei Shitara
Takashi Kojima
Hiroya Taniguchi
Jun Watanabe
Itaru Endo
Takayuki Yoshino

Background:The C-TASK-FORCE phase I/II and Danish randomized phase II trials reported the promising efficacy of trifluridine/tipiracil (TAS102) plus bevacizumab (BEV) in patients with chemorefracto...

Keywords:

Internal medicine
Colorectal cancer
in patient
Bevacizumab
Medicine
Trifluridine
Oncology
Regorafenib
Chemotherapy
Retrospective cohort study
Tipiracil

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations